Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation
dc.contributor.author | Olson, Allan D. | en_US |
dc.contributor.author | Shope, Thomas C. | en_US |
dc.contributor.author | Flynn, Joseph T. | en_US |
dc.date.accessioned | 2010-06-01T20:03:28Z | |
dc.date.available | 2010-06-01T20:03:28Z | |
dc.date.issued | 2001-02 | en_US |
dc.identifier.citation | Olson, Allan D.; Shope, Thomas C.; Flynn, Joseph T. (2001). "Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation." Pediatric Transplantation 5(1): 44-50. <http://hdl.handle.net/2027.42/73184> | en_US |
dc.identifier.issn | 1397-3142 | en_US |
dc.identifier.issn | 1399-3046 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/73184 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11260488&dopt=citation | en_US |
dc.description.abstract | Because of the severe complications that may result from varicella zoster virus (VZV) infection following renal transplantation (Tx), transplanted varicella-susceptible children exposed to varicella are typically given varicella zoster immunoglobulin (VZIG) as prophylaxis or are admitted and treated with parenteral acyclovir if VZIG prophylaxis fails. As both VZIG and hospitalization are costly, prevention of varicella infection by vaccination could potentially result in significant cost savings in addition to decreasing morbidity and mortality. To test this hypothesis, we developed a decision-analysis model to evaluate the cost-effectiveness of vaccinating patients with chronic renal failure (CRF) against varicella prior to renal transplant. Under baseline assumptions, vaccination for varicella pretransplant was a cost-effective strategy, with a cost of $211 per patient vaccinated compared with $1,828 per patient not vaccinated. The magnitude of cost savings from vaccination was sensitive to variations in the cost of varicella vaccine, the percentage of patients hospitalized for treatment with acyclovir, and the percentage of patients exposed to varicella infection. One- and two-way sensitivity analyses confirmed that vaccination was the dominant cost-effective strategy under all conditions examined. We conclude that vaccination for varicella pretransplant is cost-effective for patients with CRF, and that the magnitude of cost savings is sensitive to the cost of hospitalization, the percentage of patients exposed to varicella, and the cost of varicella vaccination. Pending results of ongoing studies of the safety and efficacy of VZV vaccine in children with CRF, we recommend that VZV vaccine be given to all children with CRF. | en_US |
dc.format.extent | 121971 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Munksgaard International Publishers | en_US |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | Munksgaard | en_US |
dc.subject.other | Children | en_US |
dc.subject.other | Renal Transplantation | en_US |
dc.subject.other | Varicella | en_US |
dc.subject.other | Immunization | en_US |
dc.subject.other | Costs and Cost Analysis | en_US |
dc.title | Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Nephrology, Department of Pediatrics and Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Gastroenterology, | en_US |
dc.contributor.affiliationother | Infectious Diseases and | en_US |
dc.identifier.pmid | 11260488 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/73184/1/j.1399-3046.2001.00032.x.pdf | |
dc.identifier.doi | 10.1034/j.1399-3046.2001.00032.x | en_US |
dc.identifier.source | Pediatric Transplantation | en_US |
dc.identifier.citedreference | Hurley JK, Greenslade T, Lewy PR, Ahmadian Y, Firlit C. Varicella-zoster infections in pediatric renal transplant recipients. Arch Surg 1980: 115: 751 – 752. | en_US |
dc.identifier.citedreference | Peterson LR & Ferguson RM. Fatal central nervous system infection with varicella-zoster virus in renal trans-plant recipients. Transplantation 1984: 37: 366 – 368. | en_US |
dc.identifier.citedreference | Bourbigot B, Quillien MC, Airiau J, et al. Renal failure in the course of reactivation of varicella-zoster virus infect-ion in a renal transplant recipient. J Infect 1986: 13: 159 – 162. | en_US |
dc.identifier.citedreference | Bradley JR, Wreghitt TG, Evans DB. Chickenpox in adult renal transplant recipients. Nephrol Dial Trans-plant 1987: 1: 242 – 245. | en_US |
dc.identifier.citedreference | Leguen E, Deminiere C, Larue JR, et al. Fatal varicella or Reye's syndrome: an unusual cause of death in a renal graft recipient. Nephrol Dial Transplant 1992: 7: 158 – 160. | en_US |
dc.identifier.citedreference | Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics 1992: 90: 216 – 220. | en_US |
dc.identifier.citedreference | Vadoud-Seyedi R, Liesnard C, Willaert F, Parent D. Fatal varicella in an immunocompromised adult. Dermatology 1993: 187: 47 – 49. | en_US |
dc.identifier.citedreference | Bensousan TA, Moal MC, Vincent F, Nousbaum JB, Bourbigot B. Fulminant hepatitis revealing primary vari-ella in a renal graft recipient. Transplant Proc 1995: 27: 2512. | en_US |
dc.identifier.citedreference | Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C. Varicella zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 1997: 99: 35 – 39. | en_US |
dc.identifier.citedreference | Kashtan CE, Cook M, Chavers BM, Mauer SM, Nevins TE. Outcome of chickenpox in 66 pediatric renal trans-plant recipients. J Pediatr 1997: 131: 874 – 877. | en_US |
dc.identifier.citedreference | Rothwell WS, Gloor JM, Morgenstern BZ, Milliner DS. Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Transplantation 1999: 68: 158 – 161. | en_US |
dc.identifier.citedreference | Franco A, Marco P, Gil C, MuÑoz C, JimÉnez L. Fatal varicella with primary fibrinolysis in a renal transplant recipient. Nephrol Dial Transplant 1999: 14: 1291 – 1294. | en_US |
dc.identifier.citedreference | Parnham AP, Flexman JP, Saker BM, Thatcher GN. Primary varicella in adult renal transplant recipients: a report of three cases plus a review of the literature. Clin Transpl 1995: 9: 115 – 118. | en_US |
dc.identifier.citedreference | Tolkoff-Rubin NE & Rubin H. New strategies for the control of viral infection in organ transplantation. Clin Transpl 1995: 9: 255 – 259. | en_US |
dc.identifier.citedreference | Peter G., eds. 1997 Red Book: Report of the Committee on Infectious Diseases, 24th edn. Elk Grove Village, IL: American Academy of Pediatrics, 1997: 573 – 585. | en_US |
dc.identifier.citedreference | Zayas E, Caraballo ZG, Otero LM, DelpÍn EAS. Varicella Zoster in a transplant program: experience with 15 cases and 70 contacts. Transplant Proc 1996: 28: 3296 – 3297. | en_US |
dc.identifier.citedreference | Balfour HH, McMonigal KA, Bean B. Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients. J Antimicrob Chemother 1983: 12 ( Suppl. B ): 169 – 179. | en_US |
dc.identifier.citedreference | Hayes K, Shakuntala V, Pingle A, Dhawan IK, Masri MA. Safe use of acyclovir (Zovirax) in renal transplant patients on cyclosporine A therapy: Case reports. Trans-plant Proc 1992: 24: 1926. | en_US |
dc.identifier.citedreference | Furth SL, Sullivan EK, Neu AM, Tejani A, Fivush BA. Varicella in the first year after renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transpl 1997: 1: 37 – 42. | en_US |
dc.identifier.citedreference | Gershon AA. Immunizations for pediatric transplant patients. Kidney Int 1993: 43: S87 – S90. | en_US |
dc.identifier.citedreference | Broyer M & Boudaillez B. Varicella vaccine in children with chronic renal insufficiency. Postgrad Med J 1985: 61 ( Suppl. 4 ): 103 – 106. | en_US |
dc.identifier.citedreference | Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994: 8: 190 – 192. | en_US |
dc.identifier.citedreference | Giacchino R, Marcellini M, Timitilli A, et al. Varicella vaccine in children requiring renal or hepatic transplantation. Transplantation 1995: 60: 1055 – 1056. | en_US |
dc.identifier.citedreference | Furth SL, Neu AM, Sullivan EK, Gensler G, Tejani A, Fivush BA. Immunization practices in children with renal disease: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1997: 11: 443 – 446. | en_US |
dc.identifier.citedreference | Furth SL, Hogg R, Tarver J, Fivush BA. One year follow-up of Varivax ® in children and adolescents with chronic renal insufficiency (CRI): a report of the South-west Pediatric Nephrology Study Group. J Am Soc Nephrol 1999: 10: 164A. | en_US |
dc.identifier.citedreference | Fivush BA & Neu AM. Immunization guidelines for ped-iatric renal disease. Semin Nephrol 1998: 18: 256 – 263. | en_US |
dc.identifier.citedreference | 27. Centers for Disease Control and Prevention. Prevention of Varicella: Updated recommendations of the Ad-visory Committee on Immunization Practices (ACIP). Morbid Mortal Wkly Rep 1999: 48: 1 – 5. | en_US |
dc.identifier.citedreference | Finger R, Hughe JP, Meade BJ, Pelletier AR, Palmer CT. Age-specific incidence of chickenpox. Public Health Rep 1994: 109: 750 – 755. | en_US |
dc.identifier.citedreference | Halloren ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994: 140: 81 – 104. | en_US |
dc.identifier.citedreference | Steele RW, Coleman MA, Fiser M. Varicella zoster in hospital personnel: skin test reactivity to monitor susceptibility. Pediatrics 1982: 70: 604 – 608. | en_US |
dc.identifier.citedreference | Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 1984: 310: 1409 – 1415. | en_US |
dc.identifier.citedreference | Fishman JA & Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998: 338: 1741 – 1751. | en_US |
dc.identifier.citedreference | Klauser R, Zlabinger GJ, Traindl Franz M, et al. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients. Transplant Proc 1992: 24: 292 – 294. | en_US |
dc.identifier.citedreference | Ho M. Epidemiology of cytomegalovirus infection in man. In: Ho M, ed. Cytomegalovirus: Biology and Infection, 2nd edn. New York: Plenum Publishing, 1991: 155 – 187. | en_US |
dc.identifier.citedreference | Evans AS & Niederman JC. Epstein–Barr virus. In: Evans AS, ed. Viral Infections of Humans: Epidem-iology and Control. New York: Plenum Publishing, 1989: 265 – 292. | en_US |
dc.identifier.citedreference | Kitai IC, King S, Gafni A. An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients. Clin Infect Dis 1993: 17: 441 – 447. | en_US |
dc.identifier.citedreference | 37. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the use of live attunated varicella vaccine. Pediatrics 1995: 95: 791 – 796. | en_US |
dc.identifier.citedreference | 38. Committee on Infectious Diseases. Varicella vaccine update. Pediatrics 2000: 105: 136 – 141. | en_US |
dc.identifier.citedreference | Winsnes R. Efficacy of zoster immunoglobulin in prophy-laxis of varicella in high-risk patients. Acta Paediatr Scand 1978: 67: 72 – 82. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.